The world’s first clinical trial is currently afoot at the CERA (Centre for Eye Research Australia), in Melbourne’s Royal Victorian Eye & Ear Hospital. Reportedly, the trial would be testing the effectiveness of Vitamin B3 in the treatment of patients afflicted with glaucoma.
One of CERA’s researchers, Dr. Flora Hui, stated that when used alongside other therapies, vitamins provide the required energy needed to increase cell lives. Incidentally, this vitamin is a supplement that is easily accessible through local pharmacies. Researchers believe that it may be a viable treatment to reverse blindness in glaucoma patients and may marginally impact eye health ingredients market as well.
Reports cite that this clinical trial had been initiated post an already conducted trial on mice, that had turned out to be quite successful. It was found then, that high doses of Vitamin B3 had prevented the onset of glaucoma.
Dr. Hui was quoted stating that since glaucoma has no cure, medical research therapies focus on lowering pressure in the eye. The CERA team is hoping that vitamin B3 used with other therapies is able to prevent future progression of glaucoma.
Reports cite that the clinical trial will go on for the next six months. Results are anticipated to be on board by the end of the year. A lot seems to be at stake regarding the trial’s success, says Dr. Hui, since it would be much convenient for patients to buy a vitamin supplement off the shelf. Indeed, this would also influence further R&D programs in eye health ingredients industry.
For the record, glaucoma is a condition that affects the eyesight of 60 million people across the globe and close to 300 thousand Australian citizens. Half of these cases go undiagnosed, leading to increased severity of the disease. It is being speculated however, that if this clinical trial is successful, the spike in vitamin supplement sales may have a commendable impact on eye health ingredients market.